[go: up one dir, main page]

NO985464L - Konsentrert antistoffpreparat - Google Patents

Konsentrert antistoffpreparat

Info

Publication number
NO985464L
NO985464L NO985464A NO985464A NO985464L NO 985464 L NO985464 L NO 985464L NO 985464 A NO985464 A NO 985464A NO 985464 A NO985464 A NO 985464A NO 985464 L NO985464 L NO 985464L
Authority
NO
Norway
Prior art keywords
antibody preparation
concentrated antibody
preparation
concentrated
disclosed
Prior art date
Application number
NO985464A
Other languages
English (en)
Norwegian (no)
Other versions
NO985464D0 (no
Inventor
Julian Marcus Relton
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10794316&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO985464(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO985464D0 publication Critical patent/NO985464D0/no
Publication of NO985464L publication Critical patent/NO985464L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO985464A 1996-05-24 1998-11-23 Konsentrert antistoffpreparat NO985464L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9610992.1A GB9610992D0 (en) 1996-05-24 1996-05-24 Concentrated antibody preparation
PCT/EP1997/002595 WO1997045140A1 (en) 1996-05-24 1997-05-22 Concentrated antibody preparation

Publications (2)

Publication Number Publication Date
NO985464D0 NO985464D0 (no) 1998-11-23
NO985464L true NO985464L (no) 1999-01-18

Family

ID=10794316

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985464A NO985464L (no) 1996-05-24 1998-11-23 Konsentrert antistoffpreparat

Country Status (28)

Country Link
US (1) US6252055B1 (pt)
EP (1) EP0907378B1 (pt)
JP (1) JP3338060B2 (pt)
KR (1) KR20000015935A (pt)
CN (1) CN1219882A (pt)
AP (1) AP9801392A0 (pt)
AR (1) AR007249A1 (pt)
AT (1) ATE318146T1 (pt)
AU (1) AU731950B2 (pt)
BR (1) BR9709267A (pt)
CA (1) CA2254983A1 (pt)
CO (1) CO4850562A1 (pt)
CZ (1) CZ382498A3 (pt)
DE (1) DE69735295T2 (pt)
EA (1) EA001860B1 (pt)
ES (1) ES2258277T3 (pt)
GB (1) GB9610992D0 (pt)
ID (1) ID16966A (pt)
IL (1) IL126940A0 (pt)
IS (1) IS4892A (pt)
NO (1) NO985464L (pt)
NZ (1) NZ332625A (pt)
PE (1) PE69098A1 (pt)
PL (1) PL330111A1 (pt)
TR (1) TR199802423T2 (pt)
WO (1) WO1997045140A1 (pt)
YU (1) YU53098A (pt)
ZA (1) ZA974486B (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP1174148A4 (en) * 1999-04-28 2005-05-04 Yamanouchi Pharma Co Ltd PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME
WO2002013859A1 (fr) * 2000-08-10 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Methode permettant d'inhiber la coagulation ou la turbidite d'une solution contenant des anticorps
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6365395B1 (en) 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
AU2006202688B2 (en) * 2001-05-31 2009-01-22 Genentech, Inc. Stable liquid formulations of antibodies
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2868614A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
CA2498591A1 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
DK1441589T3 (da) * 2001-11-08 2012-08-06 Abbott Biotherapeutics Corp Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer
US7118675B2 (en) * 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
EP3578168A1 (en) 2002-02-14 2019-12-11 Chugai Seiyaku Kabushiki Kaisha Formulation of antibody-containing solutions comprising a sugar as a stabilizer
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2236154B1 (en) 2003-02-10 2018-05-30 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
AU2012202845B2 (en) * 2003-02-10 2014-09-04 Biogen Ma Inc. Immunoglobulin formulation and method of preparation thereof
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
US20070172475A1 (en) * 2004-02-12 2007-07-26 Susanne Matheus Highly concentrated, liquid formulations of anti-egfr antibodies
US20080038253A1 (en) * 2004-03-04 2008-02-14 Cascalho Marilia I Methods For Altering T Cell Diversity
WO2005112885A2 (en) 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
WO2005112894A1 (en) 2004-05-12 2005-12-01 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005112893A1 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
MX2007010971A (es) 2005-03-08 2007-09-19 Pharmacia & Upjohn Co Llc Composiciones de anticuerpo anti-citla-4.
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
NZ716641A (en) 2005-08-24 2017-06-30 Immunogen Inc Process for preparing maytansinoid antibody conjugates
KR101363777B1 (ko) * 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―１３ 항체 조성물
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
BRPI0709726A2 (pt) 2006-04-05 2011-07-26 Abbott Biotechnology Ltd. purificaÇço de anticorpo
CA2942128C (en) 2006-08-04 2019-11-26 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
JP5744513B2 (ja) * 2007-04-17 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 肺送達のための核酸微小粒子
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
CA2693443C (en) * 2007-07-17 2018-02-13 F. Hoffmann-La Roche Ag Variable tangential flow filtration
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CA2706403A1 (en) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Immunoglobulin aggregates
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20100110841A (ko) * 2007-12-28 2010-10-13 바이오인벤트 인터내셔날 에이비 배합물
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
WO2010111378A1 (en) * 2009-03-24 2010-09-30 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
SG10201401995UA (en) * 2009-05-04 2014-08-28 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
KR101912169B1 (ko) 2010-02-04 2018-10-26 체에스엘 베링 아게 면역글로불린 제제
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
CN102939098B (zh) 2010-03-01 2016-08-03 拜耳医药保健有限公司 针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体
EA032336B1 (ru) 2010-09-17 2019-05-31 Баксалта Инкорпорейтид Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
WO2012065072A2 (en) 2010-11-11 2012-05-18 Abbott Biotechnology Ltd. IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
AU2012250924B2 (en) * 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2013023362A1 (zh) * 2011-08-16 2013-02-21 深圳市卫武光明生物制品有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
SG11201400233TA (en) 2011-08-26 2014-08-28 Baxter Int Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
MX2015003007A (es) 2012-09-07 2015-06-05 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab.
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
EP2727643A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Cross-flow ultrafiltration device and method for concentration of pharmaceutical compositions
IL312865B1 (en) 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
EA201692002A1 (ru) * 2014-04-07 2017-01-30 Сиэтл Дженетикс, Инк. Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
US10400019B2 (en) * 2014-05-01 2019-09-03 Virginia Tech Intellectual Properties, Inc. Keratin nanomaterials and methods of production
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
CN106999588A (zh) 2014-12-03 2017-08-01 瑞士杰特贝林生物制品有限公司 具有增加的稳定性的包含免疫球蛋白的药物产品
JP6889149B2 (ja) 2015-08-13 2021-06-18 アムジエン・インコーポレーテツド 抗原結合タンパク質の荷電深層ろ過
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
EP3624846B1 (en) 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
US12103949B2 (en) 2018-08-14 2024-10-01 Bristol-Myers Squibb Company Protein recovery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3272680D1 (en) 1981-05-01 1986-09-25 Miles Lab Oral pharmaceutical composition containing immune globulin
JPH01268646A (ja) * 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.
DE4211169C1 (pt) * 1992-03-31 1993-06-03 Klaus Kretzschmar
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
JPH08508240A (ja) 1993-01-12 1996-09-03 ジョージ グリスティーナ，アンソニー 受動免疫の直接的濃厚伝達のための方法および組成物
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
WO1997004801A1 (en) * 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation

Also Published As

Publication number Publication date
YU53098A (sh) 2000-03-21
EA199800946A1 (ru) 1999-06-24
TR199802423T2 (xx) 1999-02-22
US6252055B1 (en) 2001-06-26
NO985464D0 (no) 1998-11-23
EA001860B1 (ru) 2001-10-22
CA2254983A1 (en) 1997-12-04
EP0907378B1 (en) 2006-02-22
AU2958997A (en) 1998-01-05
CZ382498A3 (cs) 1999-05-12
AP9801392A0 (en) 1998-12-31
WO1997045140A1 (en) 1997-12-04
DE69735295T2 (de) 2006-10-05
BR9709267A (pt) 1999-08-10
ID16966A (id) 1997-11-27
KR20000015935A (ko) 2000-03-15
PL330111A1 (en) 1999-04-26
AR007249A1 (es) 1999-10-27
AU731950B2 (en) 2001-04-05
ES2258277T3 (es) 2006-08-16
DE69735295D1 (de) 2006-04-27
EP0907378A1 (en) 1999-04-14
CN1219882A (zh) 1999-06-16
JP3338060B2 (ja) 2002-10-28
IS4892A (is) 1998-11-10
JPH11512753A (ja) 1999-11-02
IL126940A0 (en) 1999-09-22
CO4850562A1 (es) 1999-10-26
GB9610992D0 (en) 1996-07-31
PE69098A1 (es) 1998-12-02
NZ332625A (en) 2000-04-28
ZA974486B (en) 1998-11-23
ATE318146T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
NO985464L (no) Konsentrert antistoffpreparat
NO2009028I1 (no) Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasøytisk preparat
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
IS4345A (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
DK0870003T4 (da) Hydrobehandlingskatalysator: sammensætning, fremstilling og anvendelse deraf
NO965103L (no) Bicykliske aromatiske forbindelser, anvendelse derav, og farmasöytiske og kosmetiske preparater
NO974572D0 (no) Cyklodextrin-forbindelser, fremgangsmåter for fremstilling og anvendelse derav
DK0826673T3 (da) Acetamidderivater, fremgangsmåde til fremstilling deraf og medicinske præparater
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DK0871656T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
DE69828895D1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
ITRM920412A1 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiego terapeutico.
NO943682D0 (no) Imidazol-4-yl-piperidin-derivater, deres fremstilling og terapeutiske anvendelse
NO880434D0 (no) Anestetisk preparat og fremgangsmaate for bruk derav.
NO307510B1 (no) Bicykliske aromatiske forbindelser, deres anvendelse og farmasøytiske og kosmetiske preparater derav
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
NO975020D0 (no) Azacykloalkanderivater, fremstilling derav og deres anvendelse i terapi
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
NO891006D0 (no) Terapeutisk aktivt polypeptid og fremgangsmaate for dets fremstilling.
NO962477D0 (no) Benzamidderivater, deres fremstilling og deres terapautiske anvendelse
IS1877B (is) Aðferð til framleiðslu á N-metýl-3-(1-metýl-4-píperidinýl)-1H-indól-5- etansúlfonamíð og lífeðlisfræðilega viðunandi söltum þess og lausnum þeirra
NO326826B1 (no) Alfa-aminosyreamider, fremstilling og terapeutisk anvendelse derav
DK0835254T3 (da) Oxazolidinonderivater, deres fremstilling og deres terapeutiske anvendelse
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application